Corline today techs Biomedical AB (“Corline” or the “Firm”) will today techs take part as an exhibitor at BIOMEDevice in Boston, USA subsequent week. The purpose is to extend consciousness of CHS™ and set up new buyer contacts within the necessary American market.
The US medtech market accounts for 40% of the estimated $500 billion world medtech market. The USA is due to this fact a pure focus for Corline and among the firm’s most necessary prospects are firms domiciled within the nation. To additional expose the CHS™ providing to this market, Corline will probably be attending BIOMEDevice in Boston subsequent week.
BIOMEDevice brings collectively greater than 1,500 individuals and over 200 exhibitors from primarily the japanese United States. Engineers, enterprise builders and administration personnel symbolize taking part suppliers and prospects on the truthful. Widespread to those is a give attention to the event and launch of revolutionary medical expertise merchandise.
Corline Biomedical manufactures and markets its antithrombotic product CHS™ for the aim of enhancing blood compatibility for medical system implants and extracorporeal circulation gear. Clients who use CHS™ intention to enhance the operate of their product and to scale back the affected person danger related to its use.
Henrik Nittmar, CEO of Corline Biomedical AB, feedback
“Boston is without doubt one of the most necessary hubs within the US medical expertise market and it’s due to this fact pure that Corline promotes its implausible CHS™–technology to revolutionary firms within today techs the area. We all know that we’ve a really enticing supply in CHS™ and BIOMEDevice is an ideal alternative to discover a match for buyer wants and purposes the place we see nice potential.”
For questions, please contact
Henrik Nittmar, CEO
Telephone: 018-71 30 90
Redeye AB is the corporate’s Licensed Adviser
Corline Biomedical AB, listed on the First North Progress Market (CLBIO), works with the physique’s personal substance heparin and has developed a portfolio of drug candidates to be today techs used in reference to organ and cell transplantation. The corporate is within the strategy of initiating section 2 research for Renaparin®, a candidate for which Corline has acquired Orphan Drug designation in Europe and the US and is being developed to enhance the end result of kidney transplantation. The corporate has beforehand been coating medical expertise merchandise and has, amongst different issues, handled over 100,000 cardiac stents which were implanted in sufferers. The corporate has signed cooperation agreements with quite a lot of new medical expertise firms within the USA and Canada. The drug candidates and the medical units are primarily today techs based on the identical primary expertise.